Sample preservation composition

A composition with albumin and lactic acid preserves biological samples at specific sodium ion concentrations, enabling accurate analysis of their in-vivo state during transportation and preparation of sample suspensions for detailed molecular analysis.

JP2024157569APending Publication Date: 2024-11-07NIPPON BECTON DICKINSON CO LTD +1

Patent Information

Application Number
JP2024131159
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current methods for preserving and analyzing biological samples, particularly cells and tissues, fail to maintain the in-vivo state of the samples during transportation and analysis, leading to inaccurate diagnostic results due to changes in molecular expression and cell damage during handling and transport.

Method used

A composition containing albumin, lactic acid or its salt, and specific sodium ion concentrations, along with optional polysaccharides, is used to preserve samples at 0°C to 4°C, allowing for the preparation of a sample suspension using mild enzyme treatment, which can be analyzed by methods like flow cytometry to maintain the sample's original state.

Benefits of technology

The method enables long-term preservation and transportation of samples while maintaining their in-vivo state, allowing for accurate analysis of target substances, particularly immune cells, enhancing the prediction of drug responsiveness in companion diagnostics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024157569000030
    Figure 2024157569000030
  • Figure 2024157569000031
    Figure 2024157569000031
  • Figure 2024157569000032
    Figure 2024157569000032
Patent Text Reader

Abstract

To provide a composition for preserving a sample, in particular, a composition able to preserve cells or a tissue without causing a change in the state of cells, and also to provide a sample preservation method, a method for preparing a suspension containing a target object from a preserved sample, and a method for analyzing a target object in a sample.SOLUTION: The present disclosure provides a sample preservation composition containing albumin and lactic acid or a salt thereof. The concentration of sodium ions in the composition is 50-300 mmol / L. Further provided are a method for preserving a sample using the composition, a method for preparing a sample suspension, and a method for analyzing a target object in the sample suspension.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to compositions for preserving samples. The present disclosure further relates to methods for preserving samples, methods for preparing a sample suspension containing a target substance from a preserved sample, and methods for analyzing a target substance in a sample suspension. [Background technology]

[0002] It is known that cells express various molecules depending on the type of cell, and analysis of the types, functions, and expression states of molecules expressed by cells is a useful means for elucidating interactions between cells or responsiveness to drugs, etc.

[0003] Immune checkpoint inhibitors, which have attracted attention as a new cancer treatment, are drugs that enhance the antitumor immune response of immune cells by inhibiting molecules involved in immune suppression, such as PD-1 or CTLA-4, expressed on immune cells. They have been shown to have a strong and sustained tumor regression effect against various types of cancer, including malignant melanoma and gastric cancer. It is known that there are patients who respond to immune checkpoint inhibitors (responders) and patients who do not respond to immune checkpoint inhibitors (non-responders). In clinical practice, tests (companion diagnostics) are performed to predict responsiveness to immune checkpoint inhibitors before administration. However, despite the use of companion diagnostics, the response rate of immune checkpoint inhibitors is said to be 20-40%, and it cannot be said that accurate results are always obtained with existing test methods. Administration of drugs to non-responders not only brings about the economic burden of paying high medical expenses despite the lack of effect, but also mental and physical burdens associated with side effects. In addition, while new immune checkpoint inhibitors are being developed one after another, the national medical expenses are being squeezed due to the insurance coverage of new drugs. Therefore, stratifying patients into responders and non-responders has become an important issue in order to reduce the burden on patients and the national medical expenses.

[0004] It is believed that the reason why companion diagnostics do not provide accurate results is that the molecular markers used for diagnosis are inappropriate. In current companion diagnostics, the mainstream is to test the expression of PD-L1, a surface molecule of tumor cells. For example, PD-L1 IHC 22C3 pharmDx "Dako", which has been approved as a companion diagnostic for Keytruda (registered trademark), is an assay kit based on immunohistochemical staining using an anti-PD-L1 mouse monoclonal antibody. On the other hand, although immune cells including lymphocytes and macrophages play an important role in anti-tumor immune responses, the presence or absence of these immune cells and the expression of molecules in the immune cells have not been tested at all. Furthermore, there have been cases in which the treatment was effective in patients with negative PD-L1 expression in multiple types of cancer, and it has become clear that testing PD-L1 on tumor cells alone is insufficient to predict the effectiveness of immune checkpoint inhibitors.

[0005] There are several types of immune cells, and many molecules expressed by immune cells. However, immunohistochemical staining is extremely limited in that only one or two markers can be detected at a time. Therefore, in order to examine in detail the presence or absence of various immune cells around tumor tissues and the expression state of molecules in immune cells, a new analytical method capable of detecting multiple markers is required. As such an analytical method, multicolor analysis using a flow cytometer has attracted attention in recent years, but has not yet been put to practical use.

[0006] One of the reasons is that there is no means to transport tumor tissue removed from a patient from a clinical site to a testing institution while maintaining it in a state in the patient's body. Analysis such as flow cytometry is rarely performed in clinical sites, and the removed cells or tissues are usually sent to a testing institution for analysis. During transportation, the removed cells or tissues must be temporarily preserved using physiological saline, cell preservation solution, tissue preservation solution, etc., and preservation solutions for preserving cells or tissues in a living state are disclosed, for example, in Patent Document 1 and Patent Document 2. By using these preservation solutions, it is possible to preserve cells or tissues alive, but these preservation solutions are not designed to preserve cells or tissues while maintaining them in a state in the patient's body, so that the expression state of molecules in cells changes during transportation. Therefore, analysis methods that need to be performed at a testing institution do not provide results that reflect the state inside the patient's body, making it difficult to make an accurate diagnosis.

[0007] Another reason is that there is no established method for extracting immune cells and the like as individual cells (single cells) from tissue and other samples. Conventionally, cell extraction has been performed by mechanically dispersing the tissue sample using a mixer or homogenizer, followed by centrifugation. However, such mechanical dispersion methods destroy or damage a high proportion of the cells to be analyzed, making it difficult to obtain a sufficient number of live and intact cells for analysis.

[0008] Thus, there is a need for methods of preserving and analyzing samples, such as cells or tissues, without altering the state of the cells that are the subject of analysis. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Patent No. 4947948 specification [Patent Document 2] JP 2012-116823 A Summary of the Invention [Problem to be solved by the invention]

[0010] The present disclosure aims to provide a composition for preserving a sample, in particular a composition capable of preserving cells, tissues, or mixtures thereof without changing the state of the cells. Further, the present disclosure aims to provide a method for preserving a sample, a method for preparing a suspension containing a target substance from a preserved sample, and a method for analyzing a target substance contained in a sample. [Means for solving the problem]

[0011] The invention according to the present disclosure for solving the above problems has the following aspects.

[0012] (1) A composition for preserving a sample, comprising albumin and lactic acid or a salt thereof, the composition having a sodium ion concentration of 50 to 300 mmol / L.

[0013] (2) The composition described in (1), wherein the albumin is contained in an amount of 0.01 to 2% (w / v).

[0014] (3) The composition according to (1) or (2), wherein lactic acid or a salt thereof is contained in an amount of 0.1 to 100 mmol / L.

[0015] (4) The composition according to any one of (1) to (3), wherein the albumin is bovine serum albumin (BSA).

[0016] (5) The composition according to any one of (1) to (4), wherein the lactic acid or a salt thereof is sodium lactate.

[0017] (6) The composition according to any one of (1) to (5), comprising 0.01 to 10 mmol / L of potassium dihydrogen phosphate and 0.01 to 50 mmol / L of disodium hydrogen phosphate.

[0018] (7) The composition according to any one of (1) to (6), which contains a polysaccharide.

[0019] (8) The composition according to (7), wherein the polysaccharide is selected from the group consisting of trehalose, fructooligosaccharides, resistant dextrin, and mixtures thereof.

[0020] (9) The composition according to any one of (1) to (8), wherein the sample is a cell, a tissue, or a mixture thereof.

[0021] (10) The composition according to any one of (1) to (9), wherein the sample is collected from a mammal.

[0022] (11) The composition according to (10), wherein the mammal is selected from the group consisting of humans, dogs, rats, and mice.

[0023] (12) A method for preserving a sample, comprising immersing the sample in the composition according to any one of (1) to (11).

[0024] (13) The method for preserving the composition according to (12), wherein the preservation temperature is 0°C to 4°C and the composition is in a non-frozen state.

[0025] (14) A method for preparing a sample suspension containing a target substance from a sample, comprising the steps of: a) providing a composition described in any one of (1) to (11); b) immersing a sample in the composition; and c) treating the sample with an enzyme to prepare a sample suspension.

[0026] (15) The method according to (14), wherein the enzyme comprises at least one selected from the group consisting of collagenase, elastase, hyaluronidase, dispase, glycosidase, deoxyribonuclease, and trypsin.

[0027] (16) The method according to (14) or (15), wherein the target object is a cell.

[0028] (17) The method according to (16), wherein the cells include living cells.

[0029] (18) The method according to (16) or (17), wherein the cell is a tumor-infiltrating immune cell.

[0030] (19) A method for analyzing a target substance in a sample, comprising the steps of: a) providing a composition described in any one of (1) to (11); b) immersing a sample in the composition; c) treating the sample with an enzyme to prepare a sample suspension; and d) analyzing the target substance in the sample suspension.

[0031] (20) The method according to (19), wherein step d) is carried out by at least one selected from the group consisting of flow cytometry, mass cytometry, genetic analysis including single-cell genetic analysis, imaging, immunoassay, mass spectrometry, spectroscopic analysis, and combinations thereof. Effect of the Invention

[0032] The composition and sample preservation method of the present disclosure allow a sample, particularly a cell or tissue, to be preserved while maintaining its in vivo state.Furthermore, the composition and sample preservation method of the present disclosure allow a sample to be preserved for a long period of time, making it possible to transport the sample over long distances.Therefore, for example, a sample collected abroad can be transported within the country while maintaining the cell state.

[0033] Furthermore, according to the method for preparing a sample suspension of the present disclosure, it is possible to prepare a suspension of the target substance contained in the sample, particularly the target cell, while maintaining the state in which it is in the body. According to the method of the present disclosure, it is possible to prepare a sample suspension under milder conditions than conventional methods, and therefore it is possible to extract a greater number of living cells while maintaining the local state in which they are in the body than with conventional dispersion methods.

[0034] Furthermore, according to the analytical method of the present disclosure, it is possible to analyze the target substance contained in the sample, particularly the target cell, while maintaining the state in which it is in the body. This makes it possible to analyze the cell as it is in the body, and it is expected that, for example, in companion diagnostics related to immune checkpoint inhibitors, it will be possible to predict the responsiveness to the drug more accurately than before. [Brief description of the drawings]

[0035] [Figure 1] The results of flow cytometric analysis of tumor tissues according to the method described in Example 9 (control) are shown. [Diagram 2] The results of flow cytometric analysis of tumor tissues (48 hours later) according to the method described in Example 9 are shown. [Diagram 3] The results of flow cytometric analysis of tumor tissues (72 hours later) according to the method described in Example 9 are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] Hereinafter, embodiments of the present disclosure will be described, but the present disclosure is not limited to the following embodiments.

[0037] [Composition for preserving samples] The composition of the present disclosure is a composition for preserving a sample, and contains albumin and lactic acid or a salt thereof, and has a sodium ion concentration of 50 to 300 mmol / L.

[0038] The composition of the present disclosure includes albumin. Albumin is a water-soluble protein contained in cells and body fluids of animals and plants. Albumin that can be used in one embodiment of the composition of the present disclosure includes serum albumin contained in serum of vertebrates, ovalbumin contained in egg white, milk albumin contained in milk, seed albumin contained in plant seeds, and the like. Vertebrates include, but are not limited to, humans, cows, horses, rabbits, and the like. In the present disclosure, the albumin is preferably serum albumin, more preferably albumin derived from humans, cows, or horses, and most preferably bovine serum albumin (BSA).

[0039] In one embodiment, albumin is contained in the composition at a concentration of 0.01 to 2% (w / v), preferably 0.05 to 1% (w / v), more preferably 0.1 to 0.5% (w / v), and most preferably 0.1 to 0.3% (w / v).

[0040] The composition of the present disclosure comprises lactic acid or its salt. "Lactic acid or its salt" refers to lactic acid or any lactate salt that dissolves in water to produce lactate ions and cations. Examples of lactate salts include, but are not limited to, lithium lactate, sodium lactate, potassium lactate, calcium lactate, ammonium lactate, aluminum lactate, magnesium lactate, etc. Lactic acid or its salt is preferably sodium lactate.

[0041] In one embodiment, lactic acid or a salt thereof is contained in the composition so that the concentration of lactate ions in the composition is 0.1 to 100 mmol / L, preferably 1.0 to 50 mmol / L, more preferably 1.0 to 30 mmol / L, and most preferably 3.0 to 20 mmol / L.

[0042] Lactic acid has two conformations, D-form and L-form, which are enantiomeric, and lactate salts also have conformations corresponding to the structure of lactic acid. Enantiomers refer to stereoisomers that are not superimposable and are in an image-mirror relationship. An equal mixture of D-form and L-form is called a racemic mixture or DL-form. In the composition of the present disclosure, L-form and DL-form of lactic acid or its salts are preferred, and L-form is more preferred.

[0043] The composition of the present disclosure contains sodium ions at a concentration of 50 to 300 mmol / L, preferably 80 to 250 mmol / L, and more preferably 100 to 200 mmol / L. By adjusting the sodium ion concentration to this range, the composition of the present disclosure can preserve a sample, particularly cells or tissues, while maintaining the state in the body.

[0044] The sodium ion concentration is adjusted by adding a substance that dissolves in water to generate sodium ions. Examples of substances that generate sodium ions include, but are not limited to, sodium hydroxide, sodium chloride, sodium carbonate, sodium nitrate, sodium sulfate, sodium hydrogen sulfate, sodium acetate, sodium oxalate, sodium citrate, sodium dihydrogen phosphate, and disodium hydrogen phosphate. The substance that generates sodium ions is preferably sodium chloride.

[0045] The composition of the present disclosure may further include potassium dihydrogen phosphate and disodium hydrogen phosphate. In one embodiment, potassium dihydrogen phosphate is contained in the composition at a concentration of 0.01 to 10 mmol / L, preferably 0.05 to 5.0 mmol / L, and more preferably 1.0 to 2.5 mmol / L, and disodium hydrogen phosphate is contained in the composition at a concentration of 0.01 to 50 mmol / L, preferably 1.0 to 25 mmol / L, and more preferably 5 to 15 mmol / L.

[0046] The composition of the present disclosure preferably does not contain calcium ion.In the presence of calcium ion, some molecules, especially CTLA-4, may be expressed in cells.Therefore, it is difficult to preserve the sample in the composition containing calcium ion while maintaining the state immediately after collection.

[0047] The composition of the present disclosure may contain a polysaccharide. A polysaccharide is a compound resulting from dehydration of two or more monosaccharides, their substituted derivatives, or a mixture thereof. Examples of polysaccharides include, but are not limited to, disaccharides such as sucrose, lactose, maltose, and trehalose, trisaccharides such as raffinose and maltotriose, tetrasaccharides such as acarbose and stachyose, oligosaccharides such as maltooligosaccharides and fructooligosaccharides, and glycogen, starch, dextrin, and the like, which are composed of many more molecules. The polysaccharide is preferably selected from the group consisting of trehalose, fructooligosaccharides, indigestible dextrin, and mixtures thereof, and more preferably trehalose. In one embodiment, the composition of the present disclosure contains a polysaccharide at a concentration of 0.01 to 3.0% (w / v), preferably 0.03 to 1.0% (w / v), and more preferably 0.05 to 0.5% (w / v).

[0048] In one embodiment, the sample preserved by the composition of the present disclosure is selected from a cell, a tissue, or a mixture thereof.

[0049] The cells that can be preserved by the composition of the present disclosure include, but are not limited to, various cells, such as lymphocytes, stem cells, skin cells, mucosal cells, liver cells, pancreatic islet cells, nerve cells, cartilage cells, endothelial cells, epithelial cells, bone cells, muscle cells, bone marrow cells, hematopoietic stem cells, and tumor cells. When preserving cells, cells can be preserved immediately after being collected from an organism, or cells that have been artificially cultured. The cells preserved by the composition of the present disclosure may be living or dead cells, and preferably include living cells.

[0050] As used herein, "tissue" refers to a group of various types of cells. Tissues that can be preserved by the composition of the present disclosure include epithelial tissue, connective tissue including bone tissue, cartilage tissue, and blood cell tissue, nerve tissue, muscle tissue, and tumor tissue derived from these tissues. Tissues may be taken from an organism or may be artificially constructed by culturing cells. The tissue preserved by the composition of the present disclosure is preferably tumor tissue.

[0051] In one embodiment, the cells, tissues, or mixtures thereof are preferably taken from animals, more preferably from mammals, such as, but not limited to, humans, orangutans, chimpanzees, monkeys, horses, cows, pigs, dogs, rabbits, mice, rats, hamsters, guinea pigs, etc. In one embodiment, the mammal is preferably selected from the group consisting of humans, dogs, mice, rats, hamsters, and guinea pigs, more preferably humans.

[0052] The compositions of the present disclosure are particularly suitable for the preservation of tumor tissue taken from humans.

[0053] [Sample preservation method] The present disclosure further provides a method for preserving a sample.The preservation of a sample can be carried out by any method as long as the sample can be immersed in the composition of the present disclosure.For example, the immersion of a sample can be carried out by placing the collected sample in a container that has been dispensed with the composition, or by placing the collected sample in a container and then pouring the composition of the present disclosure therein.

[0054] In the sample preservation method of the present disclosure, the preservation temperature is preferably about 0°C to about 4°C, more preferably about 0°C to about 1°C, and most preferably a temperature above 0°C to 1°C or less, at which the preservation solution and the sample do not freeze. If the preservation temperature is lower than 0°C, the sample and composition may freeze, and the state of the sample may not be maintained. If the preservation temperature exceeds 4°C, the state of the sample may not be maintained.

[0055] The disclosed methods allow samples, particularly harvested cells, tissues, or mixtures thereof, to be stored for extended periods of time, such as 24 hours, 48 ​​hours, or 72 hours, while remaining in the same state as immediately after harvest.

[0056] [How to prepare sample suspension] The present disclosure further provides a method for preparing a sample suspension containing a target substance, the method comprising the steps of a) providing a composition of the present disclosure, b) immersing a sample in the composition of the present disclosure, and c) treating the sample with an enzyme to prepare a sample suspension.

[0057] The step of a) providing a composition of the present disclosure can be performed in any manner, including, for example, dispensing into a container with a lid.

[0058] b) The step of immersing the sample in the composition of the present disclosure can be performed by any method that allows the sample to be immersed. The method of immersing the sample is as described in the section [Method of preserving the sample].

[0059] c) The step of treating the sample with an enzyme to prepare a sample suspension can be carried out by any method known to those skilled in the art, provided that the enzyme treatment allows the sample, in particular cells, tissues or mixtures thereof, to be dispersed.

[0060] Any enzyme can be used for the enzyme treatment, including, but not limited to, collagenase, elastase, hyaluronidase, neutral protease including Dispase (registered trademark), glycosidase, deoxyribonuclease (DNase), and trypsin.

[0061] The enzyme treatment may also be performed using an existing cell dispersion liquid, etc. Examples of existing cell dispersion liquids include BD Horizon (trademark) Dri Tumor & Tissue Dissociation Reagent (TTDR) available from Becton Dickinson Co., Ltd. The enzyme treatment in the method of the present disclosure preferably uses TTDR.

[0062] The enzyme treatment in the method disclosed herein can sufficiently disperse a sample, particularly cells or tissues, under milder conditions than in the past. The effect of dispersing cells or tissues by enzyme treatment varies depending on factors such as the type of enzyme used, the concentration of the enzyme, the treatment temperature, and the treatment time, but in particular, the type of enzyme used and the concentration of the enzyme have a significant effect on the dispersion state of cells or tissues. In the past, in order to obtain sufficient dispersion of cells or tissues, measures such as selecting an enzyme that acts strongly on the substrate or increasing the concentration of the enzyme have been taken, but at the same time, these measures increase the risk of reducing the yield and viability of cells and causing cell dysfunction. Therefore, it has been difficult to achieve both high cell viability and sufficient dispersion of a sample while maintaining the state of the cells.

[0063] However, according to the method of the present disclosure, the sample can be sufficiently dispersed even if the conditions such as the type and concentration of enzyme, the treatment time, and the treatment temperature in the enzyme treatment are milder than those in the past, so that the survival rate and yield of cells contained in the sample can be increased, and the cells can be dispersed without changing their state. In the past, the sample, especially cells, tissues, or mixtures thereof, cannot be immersed for a long time in the preservation solution because the state of the cells or tissue changes when the sample is immersed for a long time, and therefore the cells or tissues cannot be sufficiently dispersed under mild conditions. On the other hand, although not limited thereto, the composition of the present disclosure allows the sample to be immersed for a long time, so that the liquid composition sufficiently penetrates the sample, softening the sample, and the enzyme can easily act not only on the surface but also inside of the sample, so that the sample is considered to be sufficiently dispersed even by the enzyme treatment under milder conditions than before.

[0064] The enzyme treatment can be carried out at any temperature, but in order to avoid changing the state of the sample and obtain sufficient dispersion, it is preferably carried out at 1 to 45°C, more preferably 10 to 40°C, and most preferably 15 to 30°C. The enzyme treatment may be carried out while controlling the temperature using a device such as a thermostatic water bath that can keep the temperature constant, but it can also be carried out at room temperature. Room temperature refers to a state in which the sample is neither heated nor cooled from the outside.

[0065] There is no particular limit to the time for the enzyme treatment, but in order to avoid changing the state of the sample and to obtain sufficient dispersion, the treatment time is preferably about 1 to about 60 minutes, more preferably about 5 to 30 minutes, and more preferably about 10 to 20 minutes.

[0066] The enzyme treatment may be performed in a stationary state or with stirring or shaking. In order to allow the enzyme to act evenly throughout the sample, the enzyme treatment is preferably performed with gentle shaking at a strength that does not damage the cells.

[0067] The step of preparing a sample suspension may include any number of additional operations, such as filtration, centrifugation, and staining.

[0068] The sample suspension prepared by the method of the present disclosure includes a target. The target may be any substance that can be contained in a sample. Examples of targets include, but are not limited to, cells, genes, proteins including antibodies, amino acids, and chemicals including neurotransmitters. In one embodiment, the target is a cell. The cell may be a living cell or a dead cell, but the target preferably includes a living cell.

[0069] Examples of cells that can be the target include, but are not limited to, immune cells, red blood cells, platelets, tumor cells, stem cells, skin cells, mucosal cells, liver cells, pancreatic islet cells, nerve cells, chondrocytes, endothelial cells, epithelial cells, bone cells, muscle cells, bone marrow cells, hematopoietic stem cells, etc. Immune cells include lymphocytes, including T cells, B cells, and NK cells, granulocytes, including neutrophils, eosinophils, and basophils, dendritic cells, and macrophages. The target is preferably an immune cell, more preferably a tumor-infiltrating immune cell, and most preferably a tumor-infiltrating lymphocyte (TIL).

[0070] Tumor-infiltrating immune cells refer to immune cells that infiltrate into tumor tissue, and among them, lymphocytes are specifically referred to as TILs. TILs are known to express cell surface molecules such as CD4, CD8, CTLA-4, and PD-1 depending on the cell type. TILs include CD4-positive (CD4 + ) T cells, CD8 positive (CD8 + ) T cells, regulatory T cells (Tregs) and NK cells.

[0071] [Method of analyzing the target object] The present disclosure further provides a method for analyzing a sample. The method for analyzing a sample includes the steps of: a) providing a composition according to claims 1 to 10; b) immersing a sample in the composition; c) treating the sample with an enzyme to prepare a sample suspension; and d) analyzing a target substance in the sample suspension. Steps a) to c) are as described in the section [Method for preparing a sample suspension].

[0072] d) The step of analyzing can use any analysis method.The analysis method includes, but is not limited to, flow cytometry, mass cytometry, genetic analysis including single cell genetic analysis, imaging, immunoassay, mass spectrometry, spectroscopic analysis and combinations thereof.In the method of the present disclosure, the analysis method is preferably flow cytometry and mass cytometry, more preferably flow cytometry.

[0073] According to the analytical method of the present disclosure, a sample can be analyzed without changing the target substances contained in the sample, particularly cells, from the state immediately after collection.

[0074] The analysis method of the present disclosure is suitable for analyzing cells contained in tissue, and is particularly suitable for analyzing TILs in tumor tissue by flow cytometry. According to the analysis method of the present disclosure, more living cells can be analyzed while being maintained in a state in the patient's body. Therefore, the analysis method of the present disclosure is expected to be useful for accurately predicting the responsiveness to drugs and the prognosis of patients, for example, in the companion diagnosis related to immune checkpoint inhibitors.

[0075] Furthermore, the analytical method of the present disclosure allows a collected sample to be stored for a long period of time while maintaining the same state as immediately after collection, making it possible to transport the sample over long distances. Therefore, according to the method of the present disclosure, a sample collected at a hospital, for example, can be transported to a distant analytical institution for analysis. EXAMPLES

[0076] Hereinafter, aspects of the present disclosure will be described in detail with reference to examples. However, these are merely illustrative and are not intended to narrow the scope of the present disclosure.

[0077] The cells contained in the sample suspension were labeled, and the results were analyzed by flow cytometry to analyze the number of live cells and the proportion of each cell in each cell population, thereby evaluating the performance of the composition according to the present disclosure. The cells to be analyzed were labeled using the reagents listed in Table 1 for human samples and Table 2 for mouse samples. In addition, in the human samples, BD Pharmingen™ Human BD Fc Block™ (BD) was added before antibody staining in order to prevent non-specific binding of the antibody. Furthermore, both the human and mouse samples were subjected to cell membrane fixation and permeabilization treatment using BD Pharmingen™ Transcription Factor Buffer Set (BD), and antibody staining of FoxP3 molecules in the cells was performed.

[0078] The results showed that after identifying live cells using FVS (Fixable Viability Stain), lymphocytes > CD3 + Cells>CD4 + Cells or CD8 + Gating on cells in order, CD4 + Among the cells, cells that were FoxP3 positive and CD45RA negative were defined as Treg (regulatory T cells). On the other hand, in the mouse-derived samples, cells that were FoxP3 positive and CD25 positive were defined as Treg (regulatory T cells). Therefore, the percentage of each cell is the percentage of lymphocytes in the live cell population, the percentage of CD3 in the lymphocyte population, and the percentage of Treg cells in the lymphocyte population. + Percentage of cells, CD3 + CD4 in cell population + Cells or CD8 + Percentage of cells, and CD4 + The percentage of Tregs in the cell population. CD8 + For cells and Tregs, we further + Cells and PD-1 + The cells were gated, and the number of cells per mg of tissue was calculated using absolute counting beads, BD Trucount™ Absolute Counting Tubes (Becton, Dickinson and Company, hereinafter also referred to as “BD”).

[0079] [Table 1]

[0080] [Table 2]

[0081] (Example 1: Evaluation of the effect of BSA 1) The components listed in Table 3 were dissolved in ultrapure water to prepare Composition 1 and Composition 2. Approximately 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: approximately 10 mg / piece) was mixed with approximately 15 mL of the composition and stored at a temperature of 0°C to 1°C. After 24 hours and 48 hours, the composition was removed with an aspirator, 7 mL of TTDR (BD) was added, and the tissue was treated with an enzyme while gently shaking at room temperature for 15 minutes. Then, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer BD FACSLyric (trademark) (BD). The control was operated in the same manner except that it was not stored with the composition.

[0082] [Table 3]

[0083] The results are shown in Table 4, and are expressed as the number of viable cells per 10 mg of human colon cancer tumor tissue. The results indicate that Composition 2 containing BSA enhances the cell viability compared to Composition 1 not containing BSA. Interestingly, more viable cells were detected in tissue preserved with Composition 2 than in the control.

[0084] [Table 4]

[0085] (Example 2: Evaluation of the effect of BSA 2) The components shown in Table 5 were dissolved in ultrapure water to prepare compositions 3 to 5. 6 Each was mixed with about 5 mL of the composition and stored at a temperature of 0° C. to 1° C. After 24 hours, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer.

[0086] [Table 5]

[0087] The results are shown in Table 6. The proportion of each type of cell was almost the same among Compositions 3 to 5, in which the amount of BSA added was changed.

[0088] [Table 6]

[0089] (Example 3: Evaluation of the effect of lactate ion concentration) The components listed in Table 7 were dissolved in ultrapure water to prepare compositions 6 to 9. Next, about 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: about 10 mg / piece) was immersed in about 15 mL of composition 6, and about 30 mg of tumor tissue derived from lung cancer (3 pieces: about 10 mg / piece) was immersed in about 15 mL of compositions 7 to 9, and stored at a temperature of 0°C to 1°C. After 24 hours, the composition was removed with an aspirator, 7 mL of TTDR was added, and the tissue was treated with an enzyme while gently shaking at room temperature for 15 minutes. Next, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner, except that the tissue was not preserved with the composition and the excised tissue was immediately treated with the enzyme.

[0090] [Table 7]

[0091] The results are shown in Tables 8 to 10. In all cells, CTLA-4 expression was at the same level as in the control. On the other hand, with an increase in sodium L-lactate, PD-1 expression tended to increase, especially in Treg.

[0092] [Table 8]

[0093] [Table 9]

[0094] [Table 10]

[0095] (Example 4: Evaluation of the effect of sodium ion concentration) The components listed in Table 11 were dissolved in ultrapure water to prepare compositions 10 to 13. Then, about 20 mg of spleen (2 pieces: about 10 mg / piece) excised from a mouse was immersed in about 15 mL of the composition and stored at a temperature of 0°C to 1°C. After 24 hours, the composition was removed with an aspirator, 7 mL of TTDR was added, and the tissue was treated with enzymes while gently shaking at room temperature for 15 minutes. Next, the reagents listed in Table 2 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner, except that the tissue was not preserved with the composition and the excised tissue was immediately treated with enzymes.

[0096] [Table 11]

[0097] The results are shown below. All compositions showed a significant increase in lymphocytes, CD4 + cells, Tregs, CD8 + CD3 cells were detected at a similar rate to that in the control. + Cells were detected at similar rates to the control in Compositions 9 and 10. A trend toward increased PD-1 expression was observed when the sodium ion concentration in the composition was low.

[0098] [Table 12]

[0099] (Example 5: Effect of adding polysaccharides) The components shown in Table 13 were dissolved in ultrapure water to prepare compositions 14 to 16 having the following compositions. Next, about 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: about 10 mg / piece) was immersed in about 15 mL of the composition and stored at a temperature of 0°C to 1°C. After 48 hours, the composition was removed with an aspirator, 7 mL of TTDR was added, and the tissue was treated with an enzyme while gently shaking at room temperature for 15 minutes. Next, the reagents shown in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner except that the tissue was not preserved with the composition and the excised tissue was immediately treated with the enzyme.

[0100] [Table 13]

[0101] The results are shown in Table 14. In all compositions, the proportion of each cell was similar to that of the control.

[0102] [Table 14]

[0103] (Example 6: Effect of storage temperature) Composition 17 was prepared by adding 58 mL of ultrapure water to 942 mL of GIBCO (registered trademark) D-PBS (-) (Thermo Fisher Scientific, catalog number: 14190), followed by the addition of BSA and sodium L-lactate. Subsequently, about 20 mg of spleen (2 pieces: about 10 mg / piece) excised from a mouse was immersed in about 15 mL of the composition and stored on ice and at 4°C. After 48 hours, the composition was removed with an aspirator, 7 mL of TTDR was added, and the tissue was treated with enzymes while gently shaking at room temperature for 15 minutes. Next, the reagents listed in Table 2 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner, except that the tissue was not preserved with the composition and the excised tissue was immediately treated with enzymes.

[0104] [Table 15]

[0105] The results are shown in Table 16. In terms of the number of cells per 10 mg of tissue, the number of cells detected in the tissue stored on ice was similar to that in the control, but in the tissue stored at 4°C, the number of Treg and CD8 + A decrease in the number of cells was observed, although the percentage of cells was similar to that of the control in both conditions.

[0106] [Table 16]

[0107] [Table 17]

[0108] (Example 7: Effect of calcium ions) The components shown in Table 7 were dissolved in ultrapure water to prepare Composition 7. For comparison, a glucose-free RPMI medium (Thermo Fisher Scientific) containing 0.2% BSA was prepared. 6 The cells were suspended in about 5 mL of the composition or about 5 mL of RPMI medium and stored at a temperature of 0°C to 1°C. After 24 hours, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. As a control, the tissue was not preserved in the composition and the excised tissue was immediately treated with an enzyme, but the same procedure was followed.

[0109] The results are shown in Table 18. It was shown that PBMCs stored in RPMI medium had significantly increased CTLA-4 expression, which is believed to be due to the calcium ions contained in RPMI medium enhancing CTLA-4 expression.

[0110] [Table 18]

[0111] (Example 8: Performance evaluation 1 of the composition of the present disclosure in human-derived tumor tissue) Composition 18 was prepared by adding 58 mL of ultrapure water to 942 mL of GIBCO D-PBS(-), and then adding BSA and sodium L-lactate. Composition 19 was prepared by dissolving the components listed in Table 19 in ultrapure water. Next, about 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: about 10 mg / piece) was immersed in about 15 mL of the composition and stored at a temperature of 0°C to 1°C. After 72 hours, the composition was removed with an aspirator, 7 mL of TTDR was added, and the tissue was treated with enzymes while gently shaking at room temperature for 15 minutes. Next, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner except that the tissue was not preserved with the composition and the excised tissue was immediately treated with enzymes. The test was performed with n=4 for the control and n=3 for the other cases.

[0112] [Table 19]

[0113] The results are shown in Tables 20 and 21, with the average and standard deviation (SD). In both compositions, the number of cells per 10 mg of tissue was equal to or greater than that of the control. In addition, the ratio of each cell type was almost the same in both compositions as in the control. Therefore, it was demonstrated that the composition of the present disclosure can preserve tumor tissue for a long time while maintaining TILs in the tumor localized state.

[0114] [Table 20]

[0115] [Table 21]

[0116] (Example 9: Performance evaluation 2 of the composition of the present disclosure in human-derived tumor tissue) The performance of the existing cell preservation solution was compared with that of the composition according to the present disclosure. Composition 20 was prepared by adding 58 mL of ultrapure water to 942 mL of GIBCO D-PBS(-), and then adding BSA, sodium L-lactate, and trehalose. Next, about 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: about 10 mg / piece) was immersed in about 15 mL of composition 20 or HypoThermosol (registered trademark) (HemaCare) and stored at a temperature of 0°C to 1°C. After 48 hours and 72 hours, 7 mL of TTDR was added, and the tissue was treated with enzymes while gently shaking at room temperature for 15 minutes. Next, the reagents listed in Table 1 were added to label the cells. After labeling, the sample suspension was washed and analyzed with a flow cytometer. The control was operated in the same manner except that the tissue was not preserved with the composition and the excised tissue was immediately treated with enzymes. The test was performed on n=3 for the control and 48 hours, and on n=2 for 72 hours.

[0117] [Table 22]

[0118] The results are shown in Tables 23 to 26. More viable cells were detected in tissues preserved with composition 20 of the present disclosure than in tissues preserved with HypoThermosol. This indicates that the composition of the present disclosure can enhance the viability of cells compared to existing preservation solutions. In addition, as shown in Figures 1 to 3, the expression of CD8 was significantly reduced after 72 hours in tissues preserved with HypoThermosol, but was comparable to that of the control in tissues preserved with the composition of the present disclosure. Therefore, this result indicates that the composition of the present disclosure can preserve tumor tissue while maintaining TILs in a tumor-localized state.

[0119] [Table 23]

[0120] [Table 24]

[0121] [Table 25]

[0122] [Table 26]

[0123] Example 10: Evaluation of the performance of the composition of the present disclosure on myeloid cells The performance of the composition of the present disclosure on myeloid cells was evaluated. Here, myeloid cells refer to neutrophils, eosinophils, basophils, and their precursor cells derived from bone marrow. First, the components listed in Table 19 were dissolved in ultrapure water to prepare composition 18. Next, about 30 mg of tumor tissue derived from colon cancer excised from a patient (3 pieces: about 10 mg / piece) was immersed in about 15 mL of the composition and stored at 0 to 1°C. After 48 hours and 72 hours, the reagents listed in Table 27 were added to label the cells. After labeling, the cells were washed and analyzed by a flow cytometer. As a control, the tissue was not stored in the composition and the excised tissue was immediately treated with an enzyme, but the same procedure was followed. The test was performed with n=3.

[0124] [Table 27]

[0125] The flow cytometry results were analyzed by first identifying live cells, then analyzing populations other than lymphocyte populations, and further analyzing CD14-negative and HLA-negative or low-expressing cells (CD14 - HLA g / low cells) and CD14 positive and HLA negative or low expressing cells (CD14 + HLA-positive cells (CD14 + HLA +The CD11b + CD11c + cells, and CD11b + CD33 + Cells were further gated on CD14 + HLA + In the cell population, CD68-negative and CD163-negative cells (CD68 - CD163 - cells), and CD68-negative and CD163-positive cells (CD68 - CD163 + Cells) were also gated.

[0126] The results are shown in Tables 28-29. At any time, the number of cells detected was equal to or greater than that of the control. The ratio of each type of cell was almost the same as that of the control. Therefore, it was shown that the analysis method of the present disclosure can detect more live cells while maintaining the state of the cells even in myeloid cells.

[0127] [Table 28]

[0128] [Table 29]

Claims

1. A composition for preserving a sample, comprising: Albumin, Lactic acid or a salt thereof, wherein a sodium ion concentration in the composition is 50 to 300 mmol / L.

2. The composition of claim 1, wherein the albumin is present in an amount of 0.01 to 2% (w / v).

3. The composition according to claim 1 or 2, wherein the lactic acid or a salt thereof is contained in an amount of 0.1 to 100 mmol / L.

4. The composition of any one of claims 1 to 3, wherein the albumin is bovine serum albumin (BSA).

5. The composition according to any one of claims 1 to 4, wherein the lactic acid or a salt thereof is sodium lactate.

6. 0.01 to 10 mmol / L of potassium dihydrogen phosphate; 0.01 to 50 mmol / L of disodium hydrogen phosphate; The composition according to any one of claims 1 to 5, comprising:

7. The composition of any one of claims 1 to 6, wherein the composition comprises a polysaccharide.

8. 8. The composition of claim 7, wherein the polysaccharide is selected from the group consisting of trehalose, fructooligosaccharides, resistant dextrin, and mixtures thereof.

9. The composition according to any one of claims 1 to 8, wherein the sample is a cell, a tissue, or a mixture thereof.

10. The composition according to any one of claims 1 to 9, wherein the sample is taken from a mammal.

11. The composition of claim 10, wherein the mammal is selected from the group consisting of a human, a dog, a rat, and a mouse.

12. A method for preserving a sample, comprising immersing the sample in the composition according to any one of claims 1 to 11.

13. The method for preserving the composition according to claim 12, wherein the preservation temperature is 0°C to 4°C and the composition is in a non-frozen state.

14. A method for preparing a sample suspension containing a target substance from a sample, comprising the steps of: a) providing a composition according to any one of claims 1 to 11; b) immersing a sample in said composition; c) treating the sample with an enzyme to prepare a sample suspension; A method comprising:

15. 15. The method of claim 14, wherein the enzyme comprises at least one selected from the group consisting of collagenase, elastase, hyaluronidase, dispase, glycosidase, deoxyribonuclease, and trypsin.

16. The method of claim 14 or 15, wherein the target object is a cell.

17. The method of claim 16 , wherein the cells comprise living cells.

18. The method of claim 16 or 17, wherein the cell is a tumor-infiltrating immune cell.

19. 1. A method for analyzing an entity in a sample, comprising: a) providing a composition according to any one of claims 1 to 11; b) immersing a sample in said composition; c) treating the sample with an enzyme to prepare a sample suspension; d) analyzing the sample suspension for targets; The method includes:

20. 20. The method of claim 19, wherein step d) is performed by at least one selected from the group consisting of flow cytometry, mass cytometry, genetic analysis including single cell genetic analysis, imaging, immunoassay, mass spectrometry, spectroscopic analysis, and combinations thereof.

Citation Information

Patent Citations

  • JP1974047948A

  • Biological tissue preservation solution and method for using the same

    JP2012116823A

Cited By

  • Mother substrate for display device and display device

    CN121666087A